Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001724786 | SCV001950116 | likely pathogenic | Severe myoclonic epilepsy in infancy | 2022-02-11 | criteria provided, single submitter | clinical testing | This variant was identified as de novo (maternity and paternity confirmed)._x000D_ Criteria applied: PS2, PM2_SUP, PM5_SUP, PP2, PP3 |
3billion | RCV001724786 | SCV005905682 | likely pathogenic | Severe myoclonic epilepsy in infancy | 2023-11-22 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product [REVEL: 0.95 (>=0.6, sensitivity 0.68 and specificity 0.92); 3Cnet: 0.99 (>=0.6, sensitivity 0.72 and precision 0.9)]. Same nucleotide change resulting in same amino acid change has been previously reported to be associated with SCN1A related disorder (ClinVar ID: VCV001297050 /PMID: 31864146). The variant has been previously reported as de novo in a similarly affected individual (PMID: 31864146). A different missense change at the same codon (p.Asn416Lys) has been reported to be associated with SCN1A related disorder (ClinVar ID: VCV000651325 /PMID: 31440721). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. |